KAM
ARRY

Kazazian Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Kazazian Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,564
Closed -$222K – 73
2018
Q4 		$222K Sell
15,564
-3,149
-17% -$47.8K 0.3% 51
2018
Q3 		$284K Hold
18,713
– – 0.27% 70
2018
Q2 		$314K Sell
18,713
-716
-4% -$11.4K 0.29% 68
2018
Q1 		$317K Sell
19,429
-9,938
-34% -$159K 0.33% 61
2017
Q4 		$376K Buy
29,367
+17,681
+151% +$201K 0.38% 59
2017
Q3 		$144K Buy
+11,686
New +$109K 0.18% 63

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kazazian Asset Management's ARRY Position: Q1 2019 in Review

Kazazian Asset Management sold out of Array Biopharma Inc (ARRY) in Q1 2019, closing a stake of 15,564 shares — an estimated $222K sold.

Kazazian Asset Management first reported a position in ARRY in Q3 2017 and held it in 6 quarters. The position peaked at $376K in Q4 2017. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

  • Kazazian Asset Management reported no remaining Array Biopharma Inc position as of Q1 2019 after selling out during the quarter.
  • Kazazian Asset Management sold 15,564 Array Biopharma Inc shares in Q1 2019, an estimated $222K.
  • Kazazian Asset Management first reported a position in Array Biopharma Inc in Q3 2017 and held it in 6 quarters.
  • Kazazian Asset Management's Array Biopharma Inc position peaked at $376K in Q4 2017.
  • 268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.